Literature DB >> 32735870

Successful canakinumab treatment for activated innate response in idiopathic Castleman's disease with multiple heterozygous MEFV exon 2 variants.

Yushiro Endo1, Tomohiro Koga2, Masataka Umeda1, Kaori Furukawa1, Motoi Takenaka3, Atsushi Kawakami1.   

Abstract

Entities:  

Keywords:  Canakinumab; Castleman's disease; Familial Mediterranean fever; IL-1 inhibitors

Year:  2020        PMID： 32735870     DOI： 10.1016/j.clim.2020.108547

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


× No keyword cloud information.
  3 in total

Review 1.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

2.  Candidate biomarkers for idiopathic multicentric Castleman disease.

Authors:  Remi Sumiyoshi; Tomohiro Koga; Atsushi Kawakami
Journal:  J Clin Exp Hematop       Date:  2022

3.  Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease.

Authors:  Yushiro Endo; Tomohiro Koga; Yoshihumi Ubara; Remi Sumiyoshi; Kaori Furukawa; Atsushi Kawakami
Journal:  Clin Exp Immunol       Date:  2021-07-26       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.